Download Bibliografia

Bibliografia
Alderman EL, Haskell WL, Fair JM et al.
Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary
Risk Intervention Project (SCRIP).
Circulation 1991;84(suppl 2): II-140.
Assmann G, Cuilen P, Schulte H.
The Munster Heart Study (PROCAM). Results of follow-up at 8 years.
Eur Heart J 1998;19(suppl A):A2-A11.
Biankenhorn DH, Azen SP, Kramsch DM et al.
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis
Regression Study (MARS).
Ann Intern Med 1993;119:969 - 976.
Brown G, Albers JJ, Fisher LD et al.
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with
high levels of apolipoprotein B.
New Engl J Med 1990;323:1289 - 1298.
Buchwald H, Varco RL, Matts JP et al.
Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in
patients with hypercholesterolemia. Report of the Program on the Surgical Control of the
Hyperlipidemias (POSCH).
N Engl J Med 1990;323:946-955.
Carlson LA, Rosenhamer G.
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by
combined treatment with clofibrate and nicotinic acid.
Acta Med Scand 1988;223:405 - 418.
Chen Z, Peto R, Collins R et al.
Serum cholesterol concentration and coronary heart disease in population with low cholesterol
concentrations.
BMJ 1991;303:276-282.
Chen Z, Peto R, Collins R et al.
Serum cholesterol concentration and coronary heart disease in population with low cholesterol
concentrations.
BMJ 1991;303:276-282.
Castelli WP, Andecson K, Wilson PW et al.
Lipids and risk of coronary heart disease. The Framingham Study.
Ann Epidemiol 1992;2:23-28.
Davey Smith G, Pekkanen J.
Should there be a moratorium on the use of cholesterol lowering drugs?
BMJ 1992;304:431-434.
Downs JR, Clearfield M, Weis S et al.
Primary prevention of acute coronary events with lovastatin in men and women with average
cholesterol levels. Results of AFCAPS/TexCAPS.
JAMA 1998;279:1615 - 1622.
Gould AL, Rossouw JE, Santanello NC et al.
Cholesterol reduction yields clinical benefit. Impact of statin trials.
Circulation 1998;97:946 - 952.
Henderson AH.
Coronary heart disease: overview.
Lancet 1996;348 (suppl I): S1-S4.
Hokanson JE, Austin MA.
Plasma triglycecide level is a risk factor for cardiovascular disease independent of high-density
lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.
J Cardiovasc Risk 1996; 3:213-219.
International Task Force for Prevention of Coronary Heart Disease.
Recommendations of the European Atherosclerosis Society prepared by the International Task
Force for the Prevention of Coronary Heart Disease.
Nutr Metab Cardiovasc Dis 1992;2:113 - 156.
Jukema JW, Bruschke AVG, Van Boven AJ et al.
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease
in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression
Growth Evaluation Statin Study (REGRESS).
Circulation 1995;91:2528 - 2540.
LaRosa JC, Hunninghake D, Bush D et al.
The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and
coronary heart disease.
Circulation 1990; 81:1721 - 1733.
Lipid Research Clinics Program.
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I.
Reduction in incidence of coronary heart disease.
JAMA 1984;251:351 - 364.
MAAS investigators.
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS).
Lancet 1994;344:633 - 638.
Manninen V, Elo MO, Frick MH et al.
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart
Study.
JAMA 1988; 260:641 - 651.
Martin MJ, Hutley SB, Browner WS et al.
Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.
Lancet 1986;2: 933 - 936.
Muldoon MF, Manuck SB, Matthews KA.
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention
trials.
BMJ 1990;301:309 - 314.
Murray CJL, Lopez AD.
Mortality by cause for eight regions of the world: Global Burden of Disease Study.
Lancet 1997(a);349:1269 - 1276.
Murray CJL, Lopez AD.
Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global
Burden of Disease Study.
Lancet 1997(b);349:1347-1352.
National Cholesterol Education Program.
Second Report of the National Cholesterol Education Program (NCEP) on the Detection,
Evaluation, and Treatment of High Blood Pressure in Adults (Adult Treatment Panel ll).
Circulation 1994;89:1329 - 1445.
Oliver MF.
Doubts about preventing coronary heart disease.
Multiple interventions in middle aged men may do more harm than good.
BMJ 1992;304: 393 - 394.
Pearson TA, Laurora IM.
Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP).
Circulation 1997;96(suppl):abstract 361.
Pyocala K, De Backer G, Graham I et al.
Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of
the European Society of Cardiology, European Atherosclerosis Society and European Society of
Hypertension.
Eur Heart J 1994;15:1300 - 1331.
Pedersen TR et al for the Scandinavian Simvastatin Survival Study Group.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the
Scandinavian Simvastatin Survival Study (4S).
Circulation 1998;97:1453 - 1460.
Pitt B, Mancini GBJ, Ellis SG et al.
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in
atherosclerosis progression and clinical events.
J Am Coll Cardiol 1995;26:1133 - 1139.
Post Coronary Artery Bypass Graft Trial Investigators.
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose
anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
N Engl J Med 1997;336:153 - 162.
Rackley CE.
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery
disease.
Clin Cardiol 1996;19;683 - 689.
Rossouw JE, Lewis B, Rifkind BM.
The value of lowering cholesterol after myocardial infarction.
N Engl J Med 1990;323:1112 - 1119.
Sacks FM, Pfeffer MA, Moye LA et al, for the Cholesterol and Recurrent Events Trial Investigators.
The effect of pravastatin on coronary events after myocardial infarction in patients with average
cholesterol levels.
N Engl J Med 1996;335: 3001 - 3009.
Sacks FM, Moye LA, Davis BR et al.
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent
coronary events in the Cholesterol and Recurrent Events Trial.
Circulation 1998;97:1446 - 1452.
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S).
Lancet 3 994;344:1383 - 1389.
Shepherd J, Cobbe SM, Ford I et al, for the West of Scotland Coronary Prevention Study Group.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med 1995;333:1301 - 1307.
Simes RJ, Baker S, MacMahon S et al.
Pravastatin reduces total mortality in patients with coronary heart disease and average
cholesterol levels: relationship of baseline cholesterol and treatment effects in the LIPID Trial.
Presented at the 47th Annual Scientific Session of the American College of Cardiology, March 29 - April
1, 1998, Atlanta, Georgia, USA.
Simons LA.
Inter-relations of lipids and lipoproteins with coronary artery disease. Mortality in 19 countries.
Am J Cardiol 1986;57:5G-10G
Verschuren WM, Jacobs DR, Bloemberg BP et al.
Serum total cholesterol and log-term coronary heart disease mortality in different cultures.
Twenty-five-year follow-up of the seven countries study.
JAMA 1995;274:131-136.
Waters D, Higginson t, Gladstone P et al.
Effects of monotherapy with an HMG- CoA reductase inhibitor on the progression of coronary
atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary
Atherosclerosis Intervention Trial.
Circulation 1994;89:959 - 968.
Watts GF, Lewis B, Brunt JN et al.
Effects on coronary artery disease of lipid- lowering diet, or diet plus cholestyramine, in the St
Thomas' Atherosclerosis Regression Study (STARS).
Lancet 1992;339:563 - 569.
Watts GF, Burke V, Lewis B.
Plasma low density lipoprotein cholesterol levels and progression of coronary atheroslerosis: a
metaregression analysis of angiographic trials.
Br J Cardiol 1997;4: - 70
West of Scotland Coronary Prevention Study Group.
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary
Prevention Study.
Circulation 1998;97:1440 - 1445.
Yusuf S, Anand S.
Cost of prevention. The case of lipid lowering.
Circulation 1996;93;1774 - 1776.